TW300221B - - Google Patents

Download PDF

Info

Publication number
TW300221B
TW300221B TW084104806A TW84104806A TW300221B TW 300221 B TW300221 B TW 300221B TW 084104806 A TW084104806 A TW 084104806A TW 84104806 A TW84104806 A TW 84104806A TW 300221 B TW300221 B TW 300221B
Authority
TW
Taiwan
Prior art keywords
patent application
dimethyl
compound
ylmethyl
cns
Prior art date
Application number
TW084104806A
Other languages
English (en)
Chinese (zh)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of TW300221B publication Critical patent/TW300221B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Inorganic Insulating Materials (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
TW084104806A 1994-05-24 1995-05-16 TW300221B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/248,288 US5567824A (en) 1994-05-24 1994-05-24 Palladium catalyzed ring closure of triazolyltryptamine

Publications (1)

Publication Number Publication Date
TW300221B true TW300221B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-03-11

Family

ID=22938473

Family Applications (1)

Application Number Title Priority Date Filing Date
TW084104806A TW300221B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1994-05-24 1995-05-16

Country Status (24)

Country Link
US (1) US5567824A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0763032B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3947216B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100385027B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN1157390C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE252095T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU688505B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69531939T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0763032T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2207648T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI116899B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1041262B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP950304B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU226460B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9605838A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ285539A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT763032E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO118586B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2138496C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK284495B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW300221B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA52586C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1995032197A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU49345B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6542896A (en) * 1995-07-11 1997-02-10 Merck & Co., Inc. A triazolylmethyl-indole ethylamine bisulfate salt
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
US5811551A (en) * 1996-08-13 1998-09-22 Merck & Co., Inc. Palladium catalyzed indolization
US5808064A (en) * 1996-08-13 1998-09-15 Merck & Co., Inc. Palladium catalyzed indolization
US5877329A (en) * 1996-08-13 1999-03-02 Merck & Co., Inc. Palladium catalyzed indolization
WO1998006725A1 (en) * 1996-08-13 1998-02-19 Merck & Co., Inc. Palladium catalyzed indolization
HK1045998B (zh) * 1999-06-28 2005-06-03 詹森药业有限公司 呼吸道合胞病毒复制抑制剂
ES2204303B2 (es) * 2002-08-07 2004-12-16 Laboratorios Vita, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo.
CA2552663A1 (en) * 2004-01-09 2005-07-28 Ratiopharm Gmbh Crystalline forms of rizatriptan benzoate
ES2340861T3 (es) * 2004-01-28 2010-06-10 Ratiopharm Gmbh Procedimientos de sintesis e intermedios para la fabricacion de rizatriptan.
PA8626701A1 (es) * 2004-03-26 2006-05-16 Wyeth Corp Procedimientos para la preparacion de compuestos aminoarilos yodados
WO2006082598A2 (en) * 2005-02-01 2006-08-10 Natco Pharma Limited Novel crystalline forms of rizatriptan benzoate
WO2006137083A1 (en) * 2005-06-20 2006-12-28 Natco Pharma Limited Improved process for the preparation of rizatriptan benzoate
US20090062550A1 (en) * 2005-11-14 2009-03-05 Matrix Laboratories Ltd Process for the Large Scale Production of Rizatriptan Benzoate
EP1981860B1 (en) * 2006-01-19 2011-05-25 Matrix Laboratories Ltd Conversion of aromatic diazonium salt to aryl hydrazine
AU2008259518A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
BR112018015367A2 (pt) 2016-01-27 2018-12-18 Instar Tech A S carreadores oromucosais de nanofibra para tratamento terapêutico

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
CA2084531A1 (en) * 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
GB9215526D0 (en) * 1992-07-22 1992-09-02 Merck Sharp & Dohme Chemical process

Also Published As

Publication number Publication date
AU2467195A (en) 1995-12-18
DE69531939T2 (de) 2004-07-29
CN1322725A (zh) 2001-11-21
KR100385027B1 (ko) 2003-08-14
DE69531939D1 (de) 2003-11-20
HU226460B1 (en) 2008-12-29
AU688505B2 (en) 1998-03-12
HK1009045A1 (en) 1999-05-21
DK0763032T3 (da) 2004-02-09
SK149896A3 (en) 1997-09-10
CN1157390C (zh) 2004-07-14
JP3947216B2 (ja) 2007-07-18
PT763032E (pt) 2004-02-27
KR970703336A (ko) 1997-07-03
FI964669L (fi) 1996-11-22
FI964669A0 (fi) 1996-11-22
HK1041262B (zh) 2005-04-15
MX9605838A (es) 1997-12-31
ATE252095T1 (de) 2003-11-15
HUT76469A (en) 1997-09-29
CN1077104C (zh) 2002-01-02
RU2138496C1 (ru) 1999-09-27
UA52586C2 (uk) 2003-01-15
YU49345B (sh) 2005-07-19
US5567824A (en) 1996-10-22
EP0763032B1 (en) 2003-10-15
YU33495A (sh) 1998-07-10
EP0763032A1 (en) 1997-03-19
ES2207648T3 (es) 2004-06-01
RO118586B1 (ro) 2003-07-30
NZ285539A (en) 1998-06-26
HRP950304B1 (en) 2004-12-31
FI116899B (fi) 2006-03-31
JPH10500680A (ja) 1998-01-20
HK1041262A1 (en) 2002-07-05
CN1152920A (zh) 1997-06-25
HRP950304A2 (en) 1997-08-31
HU9603236D0 (en) 1997-01-28
WO1995032197A1 (en) 1995-11-30
SK284495B6 (sk) 2005-05-05

Similar Documents

Publication Publication Date Title
TW300221B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
US20080161581A1 (en) Synthetic methodology for the reductive alkylation at the c-3 position of indoles
LT4578B (lt) Chromano dariniai
TW201310B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP2015523985A (ja) ジアリールヨードニウム塩を製造するための方法及び反応剤
US4258059A (en) Amino-benzamides
EA003244B1 (ru) Катализируемая палладием индолизация
JPS6117826B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP3020011B2 (ja) ヘキサヒドロピリダジン−1,2−ジカルボキシ誘導体の製造法
JPH08509491A (ja) 胃腸疾患の治療に有用なエタノールアミン誘導体
JPS6225666B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA2190851C (en) Palladium catalyzed ring closure of triazolyl tryptamine
WO2002076955A1 (en) Process for preparing fluconazole and its crystal modifications
JPS5858335B2 (ja) アルフア − チカンアセトンノセイゾウホウ
FR2473520A1 (fr) Nouveaux derives imidazolylethoxymethyliques du pyrazole, utiles notamment comme agents antimicrobiens, et leur procede de preparation
JPS5995232A (ja) ケテン―0,0―アセタール
JPH01216965A (ja) 2−アルコキシブロピオン酸アミド誘導体の製造方法
JPH0466572A (ja) N―アルキルピラゾール誘導体の製法
HK1009045B (en) Palladium catalyzed ring closure of triazolyl tryptamine
JPH062745B2 (ja) インダン誘導体
JPH0338549A (ja) 置換レゾルシン酸エステル類の製造法
JPS6058976A (ja) インドール誘導体およびその医薬への応用
JPS6356217B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MXPA99011854A (en) Method for the preparation of citalopram
CH573891A5 (en) 2-(4-Isobutylphenyl) butyric acid and salts - with antiinflammatory activity prepd. by converting 4-isobutyl-phenyl-acetonitrile into its alpha-ethyl deriv., then hydrolysing

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent
MK4A Expiration of patent term of an invention patent